Artivion, Inc.
AORT Healthcare Medical Devices
Artivion, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $441.3 million, up 13.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.3%, EPS fell 1,033.3%, free cash flow fell 202.5% and total debt rose 67.5%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for five, operating cash flow growth for three.
Follow AORT
Artivion, Inc. (AORT) P/E ratio
Artivion, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1,741× (May 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 217× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 584× | — |
| FY2018 | 0.0× | — |
| FY2017 | 174× | 201.58% |
| FY2016 | 57.6× | (25.23%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 146× | (32.56%) |
| Dec 2025 | 217× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PRCT PROCEPT BioRobotics Corporation compare | n/m |
| AORT Artivion, Inc. | n/m |
| CBLL CeriBell, Inc. compare | n/m |
| IART Integra LifeSciences Holdings Corporation compare | n/m |
| LMRI Lumexa Imaging Holdings, Inc. compare | n/m |
| ENOV Enovis Corporation compare | n/m |
| TNDM Tandem Diabetes Care, Inc. compare | n/m |
| BVS Bioventus Inc. compare | 16.4× |
| IRMD iRadimed Corporation compare | 48.5× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)